University of Sussex
Browse
- No file added yet -

Elucidation of focal adhesion kinase as a modulator of migration and invasion and as a potential therapeutic target in chronic lymphocytic leukemia

Download (1.98 MB)
journal contribution
posted on 2023-06-10, 03:07 authored by Thomas Burley, Andrew Hesketh, Giselda Bucca, Emma KennedyEmma Kennedy, Eleni LadikouEleni Ladikou, Benjamin TowlerBenjamin Towler, Simon MitchellSimon Mitchell, Colin P Smith, Christopher Fegan, Rosalynd Johnston, Andrea PepperAndrea Pepper, Christopher PepperChristopher Pepper
The retention and re-migration of Chronic Lymphocytic Leukemia cells into cytoprotective and proliferative lymphoid niches is thought to contribute to the development of resistance, leading to subsequent disease relapse. The aim of this study was to elucidate the molecular processes that govern CLL cell migration to elicit a more complete inhibition of tumor cell migration. We compared the phenotypic and transcriptional changes induced in CLL cells using two distinct models designed to recapitulate the peripheral circulation, CLL cell migration across an endothelial barrier, and the lymph node interaction between CLL cells and activated T cells. Initially, CLL cells were co-cultured with CD40L-expressing fibroblasts and exhibited an activated B-cell phenotype, and their transcriptional signatures demonstrated the upregulation of pro-survival and anti-apoptotic genes and overrepresentation of the NF-?B signaling pathway. Using our dynamic circulating model, we were able to study the transcriptomics and miRNomics associated with CLL migration. More than 3000 genes were altered when CLL cells underwent transendothelial migration, with an overrepresentation of adhesion and cell migration gene sets. From this analysis, an upregulation of the FAK signaling pathway was observed. Importantly, PTK2 (FAK) gene expression was significantly upregulated in migrating CLL cells (PTK2 Fold-change = 4.9). Here we demonstrate that TLR9 agonism increased levels of p-FAK (p = 0.05), which could be prevented by pharmacological inhibition of FAK with defactinib (p = 0.01). Furthermore, a reduction in CLL cell migration and invasion was observed when FAK was inhibited (p = 0.0001), supporting a role for FAK in both CLL migration and tissue invasion. When taken together, our data highlights the potential for combining FAK inhibition with current targeted therapies as a more effective treatment regime for CLL.

History

Publication status

  • Published

File Version

  • Published version

Journal

Cancers

ISSN

2072-6694

Publisher

MDPI

Issue

7

Volume

14

Page range

1-16

Article number

a1600

Department affiliated with

  • Clinical and Experimental Medicine Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2022-04-13

First Open Access (FOA) Date

2022-04-13

First Compliant Deposit (FCD) Date

2022-04-12

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC